MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ALNY Alnylam Pharmaceuticals
- 245.440
- +6.570+2.75%
Close Dec 20 16:00 ET
- 245.440
- 0.0000.00%
Post 16:59 ET
31.66BMarket Cap-93.68P/E (TTM)
247.210High235.930Low1.66MVolume239.450Open238.870Pre Close407.73MTurnover1.30%Turnover RatioLossP/E (Static)128.98MShares304.39052wk High977.85P/B31.52BFloat Cap141.97552wk Low--Dividend TTM128.43MShs Float304.390Historical High--Div YieldTTM4.72%Amplitude3.650Historical Low245.092Avg Price1Lot Size
About Alnylam Pharmaceuticals Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Company Profile
SymbolALNY
Company NameAlnylam Pharmaceuticals
Listing DateMay 27, 2004
Issue Price6.00
Founded2002
CEODr. Yvonne L Greenstreet, MB.Ch.B.
MarketNASDAQ
Employees2100
Fiscal Year Ends12-31
Address675 West Kendall Street,Henri A. Termeer Square
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-551-8200
Websitehttp://www.alnylam.com
Company Executives
- Name
- Position
- Salary
- Dr. Yvonne L Greenstreet, MB.Ch.B.
- Director and Chief Executive Officer
- 8.90M
- Kevin Joseph Fitzgerald, PhD
- Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development
- --
- Dr. Pushkal P. Garg, M.D.
- Chief Medical Officer and Executive Vice President, Development and Medical Affairs
- 3.23M
- Dr. Akshay K. Vaishnaw, M.D.,PhD
- Chief Innovation Officer
- 3.32M
- Tolga Tanguler
- Chief Commercial Officer
- 2.87M
- Jeffrey V. Poulton
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 3.22M
- Amy W. Schulman
- Chairman of the Board
- 531.36K
- Michael W. Bonney
- Director
- 467.23K
- David E.I. Pyott, M.B.A.,M.D.
- Independent Director
- 477.21K
- Dr. Elliott Sigal, M.D.,PhD
- Independent Director
- 470.11K
- Peter N. Kellogg
- Independent Director
- 658.72K
- Dr. Olivier Raymond Brandicourt, M.D.
- Independent Director
- 480.96K
- Dr. Dennis A. Ausiello, M.D.
- Independent Director
- 477.21K
- Colleen F. Reitan
- Independent Director
- 489.15K
- Dr. Phillip A. Sharp,PhD
- Independent Director
- 502.21K
- Dr. Margaret A. Hamburg, M.D.
- Independent Director
- 471.39K
- Dr. Carolyn R. Bertozzi, PhD
- Independent Director
- 668.94K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.